Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Centessa Pharmaceuticals stock
Learn how to easily invest in Centessa Pharmaceuticals stock.
Centessa Pharmaceuticals PLC ADR is a biotechnology business based in the US. Centessa Pharmaceuticals shares (CNTA) are listed on the NASDAQ and all prices are listed in US Dollars. Centessa Pharmaceuticals employs 90 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Centessa Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CNTA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Centessa Pharmaceuticals stock price (NASDAQ: CNTA)Use our graph to track the performance of CNTA stocks over time.
Centessa Pharmaceuticals shares at a glance
|Latest market close||$4.98|
|52-week range||$2.89 - $25.98|
|50-day moving average||$5.61|
|200-day moving average||$10.14|
|Wall St. target price||$10.75|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.30|
Buy Centessa Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Centessa Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Centessa Pharmaceuticals price performance over time
|1 week (2022-06-28)||8.03%|
|1 month (2022-06-06)||56.60%|
|3 months (2022-04-06)||-48.82%|
|6 months (2022-01-06)||-44.61%|
|1 year (2021-07-06)||-77.17%|
|2 years (2020-07-02)||N/A|
|3 years (2019-07-02)||N/A|
|5 years (2017-07-02)||N/A|
Centessa Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-24.1%|
|Return on equity TTM||-51.89%|
|Market capitalisation||$486.2 million|
TTM: trailing 12 months
Centessa Pharmaceuticals share dividends
We're not expecting Centessa Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
- AbbVie (ABBV.US) (3.68% forward annual dividend yield)
- Pfizer (PFE.US) (3.06% forward annual dividend yield)
Centessa Pharmaceuticals overview
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. .
Centessa Pharmaceuticals in the news
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Frequently asked questionsWhat percentage of Centessa Pharmaceuticals is owned by insiders or institutions?
Currently 1.232% of Centessa Pharmaceuticals shares are held by insiders and 85.229% by institutions. How many people work for Centessa Pharmaceuticals?
Latest data suggests 90 work at Centessa Pharmaceuticals. When does the fiscal year end for Centessa Pharmaceuticals?
Centessa Pharmaceuticals's fiscal year ends in December. Where is Centessa Pharmaceuticals based?
Centessa Pharmaceuticals's address is: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT What is Centessa Pharmaceuticals's ISIN number?
Centessa Pharmaceuticals's international securities identification number is: US1523091007
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert